Table 1 Baseline demographic and clinical findings of eyes with PCV that completed one year of intravitreal brolucizumab treatment.

From: Predicting treatment outcomes of intravitreal brolucizumab for polypoidal choroidal vasculopathy through noninvasive assessment of polypoidal lesion blood flow with optical coherence tomography angiography

 

Signal disappearance group

Signal persistence group

P value

No. of eyes

31

15

 

Age (years)

73.9 ± 7.4 (75 (56, 87))

72.0 ± 9.1 (74 (54, 85))

0.68

Male

23 (74.2%)

12 (80.0%)

0.48

BCVA (logMAR)

0.27 ± 0.30 (0.22 (− 0.08, 1.10))

0.16 ± 0.17 (0.15 (− 0.08, 0.40))

0.30

Foveal thickness (µm)

260 ± 106 (248 (113, 577))

274 ± 93 (273 (97, 435))

0.49

Central choroidal thickness (µm)

218 ± 90 (206 (77, 472))

302 ± 171 (249 (87, 752))

0.11

Height of polypoidal lesion (µm)

279 ± 149 (213 (93, 678))

331 ± 145 (314 (168, 725))

0.17

  1. PCV Polypoidal choroidal vasculopathy; BCVA Best-corrected visual acuity.
  2. Age, BCVA, foveal thickness, central choroidal thickness, height of polypoidal lesion: average ± standard deviation (median (min, max)).
Back to article page